Back to products

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

 Amsacrine

Amsacrine  is an aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

  1: Behrendt CE, Gehan EA. Treatment-subgroup interaction: an example from a published, phase II clinical trial. Contemp Clin Trials. 2009 May;30(3):279-81. Epub 2009 Feb 21. PubMed PMID: 19232549; PubMed Central PMCID: PMC2732105.

2: Kell J. Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials. 2006 May;1(2):103-11. Review. PubMed PMID: 18473961.

3: Fuertes MA, Nguewa PA, Castilla J, Alonso C, Pérez JM. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem. 2008;15(5):433-9. Review. PubMed PMID: 18288998.

4: Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O'Marcaigh A, Wheatley K, Webb DK. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006 Mar;132(5):576-83. PubMed PMID: 16445830.

5: Perel Y, Auvrignon A, Leblanc T, Michel G, Reguerre Y, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Méchinaud F, Lejars O, Piguet C, Couillaud G, Pautard B, Landman-Parker J, Thuret I, Aladjidi N, Baruchel A, Leverger G; French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia. 2005 Dec;19(12):2082-9. PubMed PMID: 16121218.

6: Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schäkel U, Soucek S, Wandt H, Ehninger G; SHG AML96 Study Group. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica. 2002 Aug;87(8):808-15. PubMed PMID: 12161356.

7: Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C. DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107. PubMed PMID: 11962518.

8: Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, Carmichael J; Cancer Research Campaing Phase I/II Trials Committee. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 2001 Apr;47(4):333-7. PubMed PMID: 11345650.

9: Qian W, Parmar MK, Sambrook RJ, Fayers PM, Girling DJ, Stephens RJ. Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. Stat Med. 2000 Oct 15;19(19):2657-74. PubMed PMID: 10986540.

10: Schofield PC, Robertson IG, Paxton JW. Inter-species variation in the metabolism and inhibition of N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol. 2000 Jan 15;59(2):161-5. PubMed PMID: 10810450.

11: Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45(5):417-22. PubMed PMID: 10803926.

12: Ortega JJ, Olivé T, Díaz de Heredia C, Coll MT, Bastida P, Massuet L. Allogeneic and autologous bone marrow transplantation in AML in first remission. The Spanish experience. Bone Marrow Transplant. 1996 Nov;18 Suppl 2:53-8. PubMed PMID: 8932800.

13: Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15;86(6):2091-7. PubMed PMID: 7662956.

14: Kreuser ED, Wadler S, Thiel E. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology. Recent Results Cancer Res. 1995;139:371-82. Review. PubMed PMID: 7597304.

15: Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs. 1995;13(1):13-21. PubMed PMID: 7499103.

16: Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P, et al. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res. 1994 Apr 15;54(8):2199-206. PubMed PMID: 8174127.

17: Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol. 1994 Apr;45(4):341-4. PubMed PMID: 7909983.

18: Joel SP, Slevin ML. Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemother Pharmacol. 1994;34 Suppl:S84-8. Review. PubMed PMID: 8070033.

19: Momparler RL, Doré BT, Labiberté J, Momparler LF. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase. Leukemia. 1993 May;7 Suppl 1:17-20. PubMed PMID: 7683351.

20: Yamazaki H, Dilworth A, Myers CE, Sinha BK. Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro. Prostate. 1993;23(1):25-36. PubMed PMID: 8393191.

21: Bishop JF. Etoposide in the treatment of leukemias. Semin Oncol. 1992 Dec;19(6 Suppl 13):33-8. Review. PubMed PMID: 1492226.

22: Schilsky RL, Ratain MJ, Vokes EE, Vogelzang NJ, Anderson J, Peterson BA. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun;19(3 Suppl 9):84-9. Review. PubMed PMID: 1641659.

23: Ehninger G, Proksch B, Wanner T, Schuler U, Busch FW, Schmidt H, Schleyer E, Jaschonek K, Hiddemann W. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide. Leukemia. 1992 Jun;6(6):582-7. PubMed PMID: 1602795.

24: Berman E. New drugs in acute myelogenous leukemia: a review. J Clin Pharmacol. 1992 Apr;32(4):296-309. Review. PubMed PMID: 1569232.

25: Waud WR, Gilbert KS, Harrison SD Jr, Griswold DP Jr. Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo. Cancer Chemother Pharmacol. 1992;31(3):255-7. PubMed PMID: 1361163.

26: Waud WR, Plowman J, Harrison SD Jr, Dykes DJ, Anderson WK, Griswold DP Jr. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice. Cancer Chemother Pharmacol. 1992;30(4):261-6. PubMed PMID: 1322803.

27: Steuber CP, Holbrook T, Camitta B, Land VJ, Sexauer C, Krischer J. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. Invest New Drugs. 1991 May;9(2):181-4. PubMed PMID: 1714886.

28: Jehn U, Heinemann V. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. Anticancer Res. 1991 Mar-Apr;11(2):705-11. Review. PubMed PMID: 2064323.

29: Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991 Feb 15;51(4):1129-36. PubMed PMID: 1705167.

30: Willemze R, Fibbe WE, Kluin-Nelemans JC, Falkenburg JH, Richel DJ, Peters WG, den Ottolander GJ, Brand A, Zwaan FE. Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia. Ann Hematol. 1991 Feb-Mar;62(2-3):59-63. PubMed PMID: 2031969.

31: Waud WR, Harrison SD Jr, Gilbert KS, Laster WR Jr, Griswold DP Jr. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother Pharmacol. 1991;27(6):456-63. PubMed PMID: 1849465.

32: Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, Lynch E, O'Connell MJ. Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group. Haematol Blood Transfus. 1990;33:267-70. PubMed PMID: 2182420.

33: Jehn U, Heinemann V. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Haematol Blood Transfus. 1990;33:333-8. PubMed PMID: 1691134.

34: Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group. Haematol Blood Transfus. 1990;33:277-84. PubMed PMID: 1691132.

35: Rees JK, Gray RG. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematol Blood Transfus. 1990;33:243-8. PubMed PMID: 1691131.

36: Jehn U. New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:53-8. Review. PubMed PMID: 2697402.

37: Braakhuis BJ, van Dongen GA, Bagnay M, van Walsum M, Snow GB. Preclinical chemotherapy on human head and neck cancer xenografts grown in athymic nude mice. Head Neck. 1989 Nov-Dec;11(6):511-5. PubMed PMID: 2584006.

38: Geller RB, Burke PJ, Karp JE, Humphrey RL, Braine HG, Tucker RW, Fox MG, Zahurak M, Morrell L, Hall KL, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989 Oct;74(5):1499-506. PubMed PMID: 2676014.

39: Yagoda A. The role of cisplatin-based chemotherapy in advanced urothelial tract cancer. Semin Oncol. 1989 Aug;16(4 Suppl 6):98-104. Review. PubMed PMID: 2669142.

40: Schiffer CA, Lee EJ. Approaches to the therapy of relapsed acute myeloid leukemia. Oncology (Williston Park). 1989 Aug;3(8):23-7; discussion 28. Review. PubMed PMID: 2519195.

41: Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 1989 May 15;49(10):2578-83. PubMed PMID: 2540903.

42: Zittoun R, Jehn U, Fière D, Haanen C, Löwenberg B, Willemze R, Abels J, Bury J, Peetermans M, Hayat M, et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood. 1989 Mar;73(4):896-906. PubMed PMID: 2645950.

43: Linkesch W, Michlmayr G, Gerhartz H, Illinger H, König H, Düllmann J, Keilhauer R, Moldrzyk D. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results. Onkologie. 1989 Feb;12(1):8-10. PubMed PMID: 2654791.

44: Paxton JW, Evans PC, Hardy JR. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit. Cancer Chemother Pharmacol. 1989;23(5):291-5. PubMed PMID: 2706733.

45: Kalwinsky D, Mirro J Jr, Schell M, Behm F, Mason C, Dahl GV. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol. 1988 Jul;6(7):1134-43. PubMed PMID: 3292713.

46: Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: a review. Leukemia. 1988 May;2(5):253-60. Review. PubMed PMID: 3287015.

47: Hill BT, Whelan RD, Hosking LK. Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening. Invest New Drugs. 1988 Apr;6(1):11-8. PubMed PMID: 3410662.

48: Boven E, Winograd B, Fodstad O, Lobbezoo MW, Pinedo HM. Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol. 1988 Mar;24(3):567-73. PubMed PMID: 3383962.

49: Baguley BC, Calveley SB, Harvey VJ. Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials. Eur J Cancer Clin Oncol. 1988 Feb;24(2):211-8. PubMed PMID: 3356209.

50: Jehn U, Knüppel W, Wilmanns W. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial. Onkologie. 1988 Feb;11(1):13-7. PubMed PMID: 3283620.

51: Collyn-d'Hooghe M, Bernier JL, Henichart JP. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine. Cancer Biochem Biophys. 1987 Sep;9(3):257-64. PubMed PMID: 3435897.

52: Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol. 1987 May;5(5):710-21. PubMed PMID: 3553435.

53: Van Mouwerik TJ, Caines PM, Ballentine R. Amsacrine evaluation. Drug Intell Clin Pharm. 1987 Apr;21(4):330-4. PubMed PMID: 3552546.

54: Arlin ZA, Ahmed T, Mittelman A, Feldman E, Mehta R, Weinstein P, Rieber E, Sullivan P, Baskind P. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. J Clin Oncol. 1987 Mar;5(3):371-5. PubMed PMID: 3546613.

55: Paxton JW, Evans PC, Singh RM. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. Cancer Chemother Pharmacol. 1987;20(1):13-5. PubMed PMID: 3621447.

56: Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin Hematol. 1987 Jan;24(1):40-54. Review. PubMed PMID: 3547672.

57: Marty M, Lepage E, Guy H, Bordessoule D, Desablens B, Harousseau JL, Guilhot F, Leverger G, Schaison G, Boiron M. Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study. Haematol Blood Transfus. 1987;30:50-6. PubMed PMID: 3305217.

58: Schaison G, Leverger G, Bancillon A, Marty M, Olive D, Cornu G, Griscelli C, Lemerle S, Harousseau JL, Bonnet M, et al. Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance. Haematol Blood Transfus. 1987;30:461-5. PubMed PMID: 3305213.

59: Bezwoda WR, Weaving A, Kew M, Derman DP. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. Oncology. 1987;44(4):207-9. PubMed PMID: 3039431.

60: Rees JK, Gray R, Hayhoe FG. The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia. Haematol Blood Transfus. 1987;30:35-7. PubMed PMID: 2442075.

61: Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, Hann IM, Goldman JM, Hoffbrand AV, Galton DA. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985. Haematol Blood Transfus. 1987;30:346-51. PubMed PMID: 2442074.

62: Rybak ME, Anderson JR, Poulin RF, Amrein PC, Canellos GP, Gottlieb AJ. Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972. Cancer Treat Rep. 1986 Oct;70(10):1233-4. PubMed PMID: 3530451.

63: Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. Review. PubMed PMID: 2944917.

64: Gale RP, Foon KA. Acute myeloid leukaemia: recent advances in therapy. Clin Haematol. 1986 Aug;15(3):781-810. Review. PubMed PMID: 3536241.

65: Weiss RB, Grillo-López AJ, Marsoni S, Posada JG Jr, Hess F, Ross BJ. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol. 1986 Jun;4(6):918-28. PubMed PMID: 3519882.

66: Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Browman G, Miller KB, et al. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. Cancer Treat Rep. 1986 Apr;70(4):455-9. PubMed PMID: 3516395.

67: Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan;70(1):73-80. PubMed PMID: 3753662.

68: Cassileth PA, Gale RP. Amsacrine: a review. Leuk Res. 1986;10(11):1257-65. Review. PubMed PMID: 3540460.

69: Peters WG, Willemze R, Colly LP. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma. Scand J Haematol Suppl. 1986;44:7-16. PubMed PMID: 3515513.

70: Dhaliwal HS, Shannon MS, Barnett MJ, Prentice HG, Bragman K, Malpas JS, Lister TA. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside. Cancer Chemother Pharmacol. 1986;18(1):59-62. PubMed PMID: 3463435.

71: Keller AM, Tsiatis AA, Neiman RS, Glick JH, Mann RB. m-AMSA in refractory lymphoma. A phase II trial of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1985 Oct;8(5):449-52. PubMed PMID: 3840644.

72: Louie AC, Issell BF. Amsacrine (AMSA)--a clinical review. J Clin Oncol. 1985 Apr;3(4):562-92. Review. PubMed PMID: 3884748.

73: Jehn U, Zittoun R. [AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia]. Onkologie. 1985 Apr;8(2):94-5. German. PubMed PMID: 2582325.

74: Ogawa M. [Research project of cancer chemotherapy]. Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 2):595-600. Japanese. PubMed PMID: 3920968.

75: Hornedo J, Van Echo DA. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity. Pharmacotherapy. 1985 Mar-Apr;5(2):78-90. Review. PubMed PMID: 2582401.

76: Ogawa M. [Current status of clinical results of new antitumor drugs]. Gan To Kagaku Ryoho. 1985 Feb;12(2):179-88. Review. Japanese. PubMed PMID: 3918502.

77: Perry DJ, Weiss RB, Hoth DF. Hypersensitivity reactions to amsacrine. Cancer Treat Rep. 1985 Feb;69(2):199-201. PubMed PMID: 3155993.

78: Hanauske AR, Von Hoff DD. Clinical correlations with the human tumor cloning assay. Cancer Invest. 1985;3(6):541-51. Review. PubMed PMID: 3910194.

79: Carella AM, Santini G, Martinengo M, Nati S, Giordano D, Congiu A, Cerri R, Damasio E, Risso M, Rossi E, et al. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL). Haematologica. 1985 Jan-Feb;70(1):39-43. PubMed PMID: 2408974.

80: Meyskens FL Jr, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol. 1984 Nov;2(11):1223-8. PubMed PMID: 6387058.

81: Hittelman WN, Menegaz SD, McCredie KB, Keating MJ. Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse. Blood. 1984 Nov;64(5):1067-73. PubMed PMID: 6386072.

82: Larripa I, Mudry de Pargament M, Labal de Vinuesa M, Demattei A, Brieux de Salum S. In vivo and in vitro cytogenetic effects of the anti-tumor agent amsacrina (AMSA). Mutat Res. 1984 Oct;138(1):87-91. PubMed PMID: 6548548.

83: Bramwell VH, Holdener EE, Siegenthaler P, Ten Bokkel Huinink W, Bruntsch U, Renard J, van Glabbeke M. Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group. Eur J Cancer Clin Oncol. 1984 Jun;20(6):753-9. PubMed PMID: 6547674.

84: Falkson G, MacIntyre JM, Schutt AJ, Coetzer B, Johnson LA, Simson IW, Douglass HO Jr. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol. 1984 Jun;2(6):581-4. PubMed PMID: 6327926.

85: Naparstek E, Shinar E, Polliack A. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia. Isr J Med Sci. 1984 Feb;20(2):118-22. PubMed PMID: 6546740.

86: Arlin ZA. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia. Cancer Treat Rep. 1983 Nov;67(11):967-70. Review. PubMed PMID: 6357436.

87: Friedell GH. Bladder cancer chemotherapy studies supported by the National Bladder Cancer Project. Cancer Chemother Pharmacol. 1983;11 Suppl:S13-5. PubMed PMID: 6416697.

88: Ahmann FR, Meyskens FL Jr, Moon TE, Durie BG, Salmon SE. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res. 1982 Nov;42(11):4495-8. PubMed PMID: 6897012.

89: Zander AR, Vellekoop L, Dicke KA, Keating MJ, McCredie KB, Legha SS, Spitzer G, Verma D, Bodey GP. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. Cancer Treat Rep. 1982 Nov;66(11):1991-2. PubMed PMID: 6754077.

90: Weil M, Auclerc MF, Schaison G, Auclerc G, Daubrisson A, Degos L, Caro J, Marty M, Jacquillat GI. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside]. Nouv Presse Med. 1982 Oct 9;11(39):2911-4. French. PubMed PMID: 6755389.

91: Hénichart JP, Bernier JL, Catteau JP. Interaction of 4-(9-acridinylamino)aniline and derivatives with DNA. Influence of a lysylglycyl side chain on the binding parameters. Hoppe Seylers Z Physiol Chem. 1982 Aug;363(8):835-41. PubMed PMID: 6896863.

92: Dupont JC, Garay GE, Scaghone C, Pavlovsky S, Woodley PV. Trial of AMSA in acute leukemia. Cancer Treat Rep. 1982 Jul;66(7):1596-7. PubMed PMID: 7046933.

93: Lawrence HJ, Ries CA, Reynolds RD, Lewis JP, Koretz MM, Torti FM. AMSA--a promising new agent in refractory acute leukemia. Cancer Treat Rep. 1982 Jul;66(7):1475-8. PubMed PMID: 7046928.

94: Grove WR, Fortner CL, Wiernik PH. Review of amsacrine, an investigational antineoplastic agent. Clin Pharm. 1982 Jul-Aug;1(4):320-6. Review. PubMed PMID: 6764391.

95: Brenner DE, Garbino C, Kasdorf H, Villasanta U, Polcaro R, Yovarone J, Aisner J, Schiffer CA, Wiernik PH. A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. Am J Clin Oncol. 1982 Jun;5(3):291-5. PubMed PMID: 6896260.

96: Horikoshi N, Ogawa M, Inagaki J, Ezaki K, Inoue K, Okabe K, Nagata T, Aiba K, Domyo M. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)]. Gan To Kagaku Ryoho. 1982 Feb;9(2):244-9. Japanese. PubMed PMID: 6897858.

97: Macdonald JS, Marsoni S, Bruno S, Poster D. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin. Recent Results Cancer Res. 1982;80:323-30. PubMed PMID: 6977170.

98: Wilson WR, Giesbrecht JL, Hill RP, Whitmore GF. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures. Cancer Res. 1981 Jul;41(7):2809-16. PubMed PMID: 6894713.

99: Forastiere AA, Young CW, Wittes RE. A phase II trial of m-AMSA in head and neck cancer. Cancer Chemother Pharmacol. 1981;6(2):145-6. PubMed PMID: 6895486.

100: Natale RB, Gralla RJ, Wittes RE. A phase II trial of m-AMSA in patients with small-cell lung cancer. Cancer Clin Trials. 1981 Winter;4(4):393-5. PubMed PMID: 6274533.

101: Cabanillas F. [Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)]. Sangre (Barc). 1981;26(5B):885-9. Spanish. PubMed PMID: 6172860.

102: Weiss RB, Charles LM Jr, Macdonald JS. m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. Cancer Clin Trials. 1980 Fall;3(3):203-9. PubMed PMID: 7002337.

103: Rozencweig M, Von Hoff DD, Legha SS, Cysyk RL, Muggia FM. m-AMSA: a new anticancer agent. Recent Results Cancer Res. 1980;74:250-7. PubMed PMID: 6893753.

104: Goldsmith MA, Bhardwaj S, Ohnuma T, Greenspan EM, Holland JF. Phase I study of m-AMSA in patients with solid tumors and leukemias. Cancer Clin Trials. 1980 Fall;3(3):197-202. PubMed PMID: 6893683.

105: Woodcock TM, Schneider RJ, Young CW. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule. Cancer Treat Rep. 1980 Jan;64(1):53-5. PubMed PMID: 6892893.

106: Carter SK. New cytotoxic drugs for breast cancer and their clinical evaluation. Eur J Cancer. 1980;Suppl 1:265-70. Review. PubMed PMID: 6459235.